Pharvaris (NASDAQ:PHVS) Upgraded at Zacks Research

Zacks Research upgraded shares of Pharvaris (NASDAQ:PHVS) from a strong sell rating to a hold rating in a report released on Monday morning,Zacks.com reports.

PHVS has been the topic of a number of other reports. JMP Securities decreased their price target on shares of Pharvaris from $55.00 to $52.00 and set a “market outperform” rating on the stock in a research note on Wednesday, August 13th. Guggenheim initiated coverage on Pharvaris in a research report on Wednesday, June 11th. They issued a “buy” rating and a $32.00 target price on the stock. Cantor Fitzgerald lowered their price target on Pharvaris from $28.00 to $25.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 14th. Finally, Wedbush reissued an “outperform” rating and issued a $27.00 price objective on shares of Pharvaris in a research note on Thursday, June 5th. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, Pharvaris currently has an average rating of “Moderate Buy” and a consensus target price of $35.60.

Pharvaris Price Performance

NASDAQ:PHVS opened at $23.00 on Monday. The firm has a market capitalization of $1.20 billion, a P/E ratio of -6.85 and a beta of -2.81. The company’s fifty day moving average price is $20.02 and its 200-day moving average price is $17.34. Pharvaris has a 1-year low of $11.51 and a 1-year high of $26.33.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Tuesday, August 12th. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.07). Equities analysts anticipate that Pharvaris will post -2.71 EPS for the current fiscal year.

Institutional Trading of Pharvaris

A number of institutional investors have recently modified their holdings of PHVS. Soleus Capital Management L.P. grew its position in Pharvaris by 36.2% during the fourth quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company’s stock worth $15,617,000 after buying an additional 216,483 shares during the period. Octagon Capital Advisors LP raised its holdings in Pharvaris by 25.4% during the fourth quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company’s stock worth $14,914,000 after purchasing an additional 157,530 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Pharvaris by 36.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company’s stock worth $8,510,000 after purchasing an additional 118,408 shares in the last quarter. TFG Asset Management GP Ltd boosted its position in Pharvaris by 48.1% during the second quarter. TFG Asset Management GP Ltd now owns 188,100 shares of the company’s stock worth $3,311,000 after purchasing an additional 61,105 shares in the last quarter. Finally, TD Asset Management Inc grew its holdings in Pharvaris by 27.4% in the second quarter. TD Asset Management Inc now owns 99,510 shares of the company’s stock valued at $1,751,000 after purchasing an additional 21,388 shares during the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.